Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Surabgene Lomparvovec · ABBV-314, RGX-314

Gene therapy (AAV vector) · developed by AbbVie

Phase 2/3 Most advanced trial

ABBV Developer

1 Registered trials

What is Surabgene Lomparvovec?

Surabgene lomparvovec (ABBV-314, RGX-314) is an AAV5-delivered gene therapy encoding a soluble VEGF receptor that binds and neutralizes vascular endothelial growth factor. It is being studied in diabetic retinopathy.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: ABBV-314, RGX-314
Drug type: Gene therapy (AAV vector)
Therapy area: Ophthalmology
Developer: AbbVie (ABBV)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2/3
UNII: GJI4EV4B3C

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07592273	Phase 2/3	Diabetic Retinopathy	Recruiting	ABBV

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Diabetic Retinopathy

More from AbbVie

Adalimumab FDA approved Atogepant FDA approved Pivekimab Sunirine FDA approved Risankizumab FDA approved Telisotuzumab Vedotin FDA approved Upadacitinib FDA approved Venetoclax FDA approved ABBV-1042 Phase 1 ABBV-291 Phase 1 ABBV-295 Phase 2 ABBV-313 Phase 1 ABBV-324 Phase 1

Follow ABBV, the company behind Surabgene Lomparvovec

See ABBV's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ABBV catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z